Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period

Trial Profile

Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMELLI 1
  • Sponsors Sanofi
  • Most Recent Events

    • 30 Jan 2018 Planned patient number has been changed to 880.
    • 22 Jan 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2018.
    • 22 Jan 2018 Planned number of patients changed from 500 to 580.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top